GX1 Stock Overview
Operates in the biotechnology industry in Poland and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
genXone S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | zł6.10 |
| 52 Week High | zł8.70 |
| 52 Week Low | zł4.90 |
| Beta | -0.76 |
| 11 Month Change | -1.29% |
| 3 Month Change | -12.86% |
| 1 Year Change | -25.61% |
| 33 Year Change | -78.89% |
| 5 Year Change | n/a |
| Change since IPO | -85.81% |
Recent News & Updates
Shareholder Returns
| GX1 | PL Biotechs | PL Market | |
|---|---|---|---|
| 7D | 0.3% | 2.7% | -1.1% |
| 1Y | -25.6% | -12.3% | 10.6% |
Return vs Industry: GX1 underperformed the Polish Biotechs industry which returned -12.3% over the past year.
Return vs Market: GX1 underperformed the Polish Market which returned 10.6% over the past year.
Price Volatility
| GX1 volatility | |
|---|---|
| GX1 Average Weekly Movement | 6.9% |
| Biotechs Industry Average Movement | 5.3% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in PL Market | 9.0% |
| 10% least volatile stocks in PL Market | 3.2% |
Stable Share Price: GX1 has not had significant price volatility in the past 3 months.
Volatility Over Time: GX1's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of Polish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 17 | Michal Kaszuba | genxone.eu |
genXone S.A. operates in the biotechnology industry in Poland and internationally. The company operates in the field of molecular genetics and bioinformatics. It offers nucleic acid sequencing services based on nanopore sequencing technology.
genXone S.A. Fundamentals Summary
| GX1 fundamental statistics | |
|---|---|
| Market cap | zł20.04m |
| Earnings (TTM) | -zł3.75m |
| Revenue (TTM) | zł2.01m |
10.0x
P/S Ratio-5.4x
P/E RatioIs GX1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GX1 income statement (TTM) | |
|---|---|
| Revenue | zł2.01m |
| Cost of Revenue | zł1.60m |
| Gross Profit | zł414.01k |
| Other Expenses | zł4.17m |
| Earnings | -zł3.75m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 12, 2024
| Earnings per share (EPS) | -1.14 |
| Gross Margin | 20.57% |
| Net Profit Margin | -186.50% |
| Debt/Equity Ratio | 0% |
How did GX1 perform over the long term?
See historical performance and comparison